Skip to content
HOME Insights

A Reduction in Animal Testing Stems From Ncardia

Ncardia author image

By Ncardia

Ncardia post featured image

Video

An Expert’s Take on the Future of Safer Drug Development With iPSC Models

The drug development industry is entering a new era — one that relies less on animal models and more on powerful, human-relevant tools like induced pluripotent stem cells (iPSCs). As part of the FDA’s updated guidance, companies can now use non-animal methods (NAMs) to demonstrate drug safety and efficacy. And according to Ncardia’s Divisional CEO, Jeroen de Groot, iPSC models are one of the most advanced, scalable and predictive tools in that NAM toolbox. 

Watch the video to learn:

  • Why iPSC models are more predictive than traditional animal models 
  • How Ncardia’s platform supports large-scale, multi-year drug development programs  
  • What makes iPSCs a solid foundation for both human and NHP-derived NAMs 
  • How this shift is helping industry reduce cost, increase speed and improve safety predictions  

 

Ready to move beyond outdated models? Watch the video below and explore how Ncardia’s iPSC expertise can help your program move forward faster, smarter and more ethically. 

 
Topics